The global dacryocystitis market is projected to grow at a significant CAGR during the forecast period. Dacryocystitis is an in?ammation of the lacrimal sac and duct. It may be congenital or acquired. Acquired dacryocystitis assumes two main forms including acute and chronic. The primary factors that drive the growth of the market include increased prevalence of eye infections and increasing clinical research along with novel product launches. Additionally, it is also a crucial cause of ocular morbidity, both in children and adults. Hence, it requires special attention concerning the initiation of the appropriate treatment at the earliest.

Free Sample Copy @ https://www.omrglobal.com/request-sample/dacryocystitis-market

The global dacryocystitis market is geographically segmented into North America, Europe, Asia-Pacific, and the Rest of the World. North America is estimated to be the significantly growing region in the market. The regional growth of the market is attributed to the well-developed healthcare industry and the presence of leading medical laser manufactures is also attributing to the growth of the market. The US and Canada are the major countries in the region that provide a significant contribution to the growth of the market. The US is the major contributor to the market due to the presence of various government initiatives, reforms, policies, and regulations for the support of the advanced treatment of eyes. As per the studies conducted by the Texas, US-based ophthalmologist Dr. Grant D Gilliland, females are mostly affected by the disease as compared to males. Thus, rapid R&D activities regarding the dacryocystitis are likely to significantly contributes to market growth during the forecast period.

A Full Report of Global Dacryocystitis Market is Available at:
https://www.omrglobal.com/industry-reports/dacryocystitis-market

Further, as per the studies by IOSR Journal of Dental and Medical Sciences (IOSR-JDMS), chronic dacryocystitis is more common than acute dacryocystitis but also has several stages of presentation like epiphora, mucoid discharge, conjunctival hyperemia, and chronic conjunctivitis. Thus, the seriousness regarding the treatment of such eye-related disorders is likely to create scope for market growth during the forecast period.

Despite, the use of laser in dacryocystitis treatment is effective and safe which results in the treatment of various eye conditions; and the use of a laser is more advantageous as compared to other treatments for the surgery, a minute mishandling of the device can cause severe damage to the patient. Hence, skilled labor is required for the operation, and a shortage of which, may challenge the growth of the market during the forecast period.

Global Dacryocystitis Market – Segmentation
by Indication
Acute
Chronic
Others (Congenital)
Global Dacryocystitis Market – Segmentation by Region 
North America 
United States
Canada
Europe
Germany
United Kingdom
France
Spain
Italy
Rest of Europe
Asia-Pacific 
China
Japan
India
Rest of Asia-Pacific
Rest of the World

Company Profiles
Akorn, Inc.
Alembic Pharmaceuticals Ltd.
Aurobindo Pharma Ltd.
Bess Medizintechnik GmbH
Cigna
Cipla Ltd.
Eyevance Pharmaceuticals
Gunther Weiss Scientific Glass Co. Inc.
FCI Ophthalmics
GlaxoSmithKline Plc
Kaneka Corp.
LABIANA GROUP
Merck & Co. Inc.
Mylan NV
Nosch
Novartis International AG
Orex Pharma Pvt. Ltd.
Perrigo Co.
Pfizer Inc.
PRODECO PHARMA Srl
Rexall Pharmacy Group Ltd. (McKesson Corp.)
Teligent, Inc.

For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/dacryocystitis-market

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

Media Contact:

Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: [email protected] 
Contact no: +91 780-304-0404